Targets › GATA2
1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout Dec 2027.
Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'. (UniProt, P23769)
Open in Phaseline: the race on GATA2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Gene replacement therapy via allogeneic stem cell transplantation to restore functional GA | GATA2 | Phase 2 | GATA2 | Dec 2027 |
GATA2 (1)
mixed (1)
National Cancer Institute (NCI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.